Cure8 research brief
A blood biomarker that reflects neuro-immune inflammation could help track disease activity across IBD and other autoimmune conditions, but CGRP is not ready for routine clinical use yet.
Researchers, clinicians treating IBD, and patients/caregivers interested in biomarker development.
This paper is a PRISMA-compliant systematic review and meta-analysis that pooled studies measuring circulating calcitonin gene-related peptide (CGRP) levels across several autoimmune diseases, including inflammatory bowel disease (IBD).
The authors report higher average CGRP in blood (serum/plasma) in IBD as part of a broader signal across rheumatoid arthritis, psoriasis, and progressive multiple sclerosis. The review suggests CGRP behaves as a dynamic marker linked to active neuro-immune inflammation rather than a fixed diagnostic test.
The authors emphasize that clinical use would need prospective, longitudinal studies and standardized, isoform-specific assays before CGRP could be used reliably in practice. Keep the findings in perspective: this brief is based on the journal abstract provided, not a full independent appraisal of every included study.
The meta-analysis aggregates heterogeneous studies and calls for more standardized, longitudinal work.
Abstract-level summary only; authors call for prospective longitudinal studies and standardized assays. The meta-analysis pooled heterogeneous cohorts and measured circulating CGRP (serum/plasma).
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Researchers used genetics plus single-cell sequencing and ELISA to prioritize plasma protein ratios that may causally relate to ulcerative colitis. If validated in larger studies, such biomarkers could help with...
Oral and upper-GI involvement in Crohn's can be missed and may change how disease is diagnosed and managed. A focused review helps clinicians and researchers spot gaps in diagnostics and treatment research.
